Related Experiment Video
Updated: May 24, 2025

Novel Apparatus and Method for Drug Reinforcement
Published on: August 20, 2010
Novel SPAST Deletion Mutation in an American Family With Hereditary Spastic Paraplegia: A Case Report
Sydney B Bhopatkar1, Juebin Huang2
1Class of 2026, School of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
Abstract:
The diverse group of neurodegenerative disorders known as hereditary spastic paraplegia (HSP) is characterized by spasticity and weakness of the bilateral lower extremity due to degeneration of the corticospinal tract. The pathogenesis of HSP is broad, with autosomal dominant, autosomal recessive, X-linked recessive, mitochondrial inheritance, and de novo mutations reported, along with remarkable heterogeneity of mutations and clinical presentation. Of these, the most common subtype of HSP is HSP type 4 (HSP-SPG4), a result of mutations in the SPAST gene (chromosome 2p22.3) that leads to impaired activity of the microtubule-severing protein spastin. Typically presenting as an uncomplicated, autosomal dominant form of the disease, HSP-SPG4 has been documented worldwide with vast genomic variance across the SPAST gene. Despite common features in clinical phenotypes, a clear link between SPAST gene variants and disease presentation remains vague. Here, we report a novel 26.1 kb deletion in the SPAST gene (del exons 4-7) in a US family with previously undiagnosed HSP-SPG4.
Related Concept Videos
Gene Therapy
Drug Discovery: Overview
Non-nuclear Inheritance
Viral Structure
PCR
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...

